Technical Analysis for UTHR - United Therapeutics Corporation

Grade Last Price % Change Price Change
C 192.07 -3.06% -6.07
UTHR closed down 3.06 percent on Thursday, May 6, 2021, on 85 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical UTHR trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Stochastic Reached Oversold Weakness 0.00%
Earnings Movers Other 0.00%
Multiple of Ten Bullish Other 0.00%
Inside Day Range Contraction 0.00%
BB Squeeze Ended Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New Downtrend Bearish -3.06%
Older End-of-Day Signals for UTHR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day about 16 hours ago
60 Minute Opening Range Breakdown about 18 hours ago
Down 3% about 19 hours ago
Down 2 % about 19 hours ago
Down 1% about 19 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

United Therapeutics Corporation Description

United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product is Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops oral treprostinil, an orally delivered prostacyclin analog for treatment of pulmonary hypertension; Ch14.18 MAb, an antibody in Phase III clinical trials for the treatment of neuroblastoma; Beraprost 314d, which is entering Phase III clinical trails for the treatment of PAH; PLacental eXpanded cells, which are entering a Phase I trial for the treatment of PAH; and 8H9 MAb, an antibody that is under Phase I clinical trial for the treatment of metastatic brain cancer. Further, the company is involved in the pre-clinical stage of developing TransCon Treprostinil, TransCon Beraprost, and glycobiological antiviral agents for the treatment of infectious diseases, such as Hepatitis C; and engineered lungs and lung tissue, which can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Infectious Diseases Chemical Compounds Organic Compounds Hypertension Blastoma Alcohols Pulmonary Arterial Hypertension Hepatitis C Brain Cancer Pulmonary Hypertension Neuroblastoma Lung Diseases Treprostinil United Therapeutics Cac All Share Index Chronic And Life Threatening Conditions Prostacyclin Prostaglandins

Is UTHR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 212.62
52 Week Low 98.37
Average Volume 360,368
200-Day Moving Average 144.87
50-Day Moving Average 183.40
20-Day Moving Average 203.04
10-Day Moving Average 201.87
Average True Range 6.38
ADX 36.64
+DI 17.70
-DI 19.79
Chandelier Exit (Long, 3 ATRs ) 193.48
Chandelier Exit (Short, 3 ATRs ) 207.48
Upper Bollinger Band 212.41
Lower Bollinger Band 193.68
Percent B (%b) -0.09
BandWidth 9.22
MACD Line 3.59
MACD Signal Line 6.33
MACD Histogram -2.7401
Fundamentals Value
Market Cap 8.54 Billion
Num Shares 44.4 Million
EPS 10.59
Price-to-Earnings (P/E) Ratio 18.14
Price-to-Sales 4.08
Price-to-Book 1.76
PEG Ratio 7.80
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 204.64
Resistance 3 (R3) 205.15 201.47 202.55
Resistance 2 (R2) 201.47 198.27 201.22 201.85
Resistance 1 (R1) 196.77 196.29 194.93 196.26 201.15
Pivot Point 193.09 193.09 192.17 192.84 193.09
Support 1 (S1) 188.39 189.89 186.55 187.88 182.99
Support 2 (S2) 184.71 187.91 184.46 182.29
Support 3 (S3) 180.01 184.71 181.60
Support 4 (S4) 179.50